ArticleMilitary Medical Research2024
Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021.
Article in Military Medical Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07321197 (Template Lymph Node Dissection for Tumor Control in High-Risk Renal Cell Carcinoma), which is not on this map. Cited by 147 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Template Lymph Node Dissection for Tumor Control in High-Risk Renal Cell Carcinoma: A Prospective, Open-Label, Multicenter, Randomized Controlled Trial
Who cites it
147 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Efficacy and safety of blue laser vaporization of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis.The Canadian journal of urology · 2026Pooled it
- Efficacy and safety of Gepotidacin for urogenital infections: a systematic review and meta-analysis of randomized controlled trials.Infection · 2026Pooled it
- Association between periodontal disease and prostatic disease: a systematic review and meta-analysis of observational studies.The Canadian journal of urology · 2026Pooled it
- Association between SGLT2 inhibitors and genital cancer: a meta-analysis and mendelian randomization study.Journal of endocrinological investigation · 2026Pooled it
- The incidence and risk factors of urinary tract infections in patients undergoing bladder tumor resection: a systematic review and meta-analysis.BMC urology · 2025Pooled it
- Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis.Frontiers in oncology · 2025Pooled it
- Impact of remote follow-up under an intelligent medical collaboration model on health promotion and clinical outcomes in patients with urinary calculi.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Trial
- Global, regional, and national burdens of Urolithiasis in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis based on the Global Burden of Disease Study 2021.Frontiers in urology · 2025Trial
- Global burden and trends of stomach cancer, Colon and rectum cancer, peptic ulcer disease, and gastritis and duodenitis from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.Future science OA · 2026Article
- Factors associated with help-seeking for urinary symptoms among Chinese patients with bladder cancer: A qualitative study.Asia-Pacific journal of oncology nursing · 2026Article
- Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5α-reductase inhibitor-treated prostatic hyperplasia.Experimental & molecular medicine · 2026Article
- A xeno-free human iPSC-derived prostate organoid platform for multilineage differentiation and genetic manipulation.Cell reports methods · 2026Article
- Article
- Global, regional, and national burden of urolithiasis among children and adolescents, 1990-2021, with forecasts to 2050: a systematic analysis of the Global Burden of Disease Study 2021.World journal of urology · 2026Article
- Phenylalanine primes renal tubular redox vulnerability and calcium oxalate crystal retention through a PPARδ-CPT1A fatty-acid oxidation axis.Redox biology · 2026Article
- The Reality of Benign Prostatic Hyperplasia Surgery Price and Reimbursement Across Top United States Hospitals.Urology practice · 2026Article
- Identification of angiogenesis-related genes in the diagnosis of benign prostatic hyperplasia using bioinformatics analysis.Translational andrology and urology · 2026Article
- GSTM4 Suppresses Prostate Cancer Progression by Targeting TRIM27-mediated ACLY Ubiquitination and Lipid Metabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Global research landscape of benign prostatic hyperplasia (2010-2026): a bibliometric and visualized analysis revealing evolving trends, hotspots, and future frontiers.World journal of urology · 2026Article
- The association between diet-exercise patterns and self-reported prostate cancer: A cross-sectional NHANES study.Medicine · 2026Article
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe burden of common urologic diseases, including benign prostatic hyperplasia (BPH), urinary tract infections (UTI), urolithiasis, bladder cancer, kidney cancer, and prostate cancer, varies both geographically and within specific regions. It is essential to conduct a comprehensive and precise assessment of the global burden of urologic diseases.
methodsWe obtained data on incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) for the aforementioned urologic diseases by age, sex, location, and year from the Global Burden of Disease (GBD) 2021. We analyzed the burden associated with urologic diseases based on socio-demographic index (SDI) and attributable risk factors. The trends in burden over time were assessed using estimated annual percentage changes (EAPC) along with a 95% confidence interval (CI).
resultsIn 2021, BPH and UTI were the leading causes of age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR), with rates of 5531.88 and 2782.59 per 100,000 persons, respectively. Prostate cancer was the leading cause of both age-standardized mortality rate (ASMR) and age-standardized DALYs rate (ASDR), with rates of 12.63 and 217.83 per 100,000 persons, respectively. From 1990 to 2021, there was an upward trend in ASIR, ASPR, ASMR, and ASDR for UTI, while urolithiasis showed a downward trend. The middle and low-middle SDI quintile levels exhibited higher incidence, prevalence, mortality, and DALYs related to UTI, urolithiasis, and BPH, while the high and high-middle SDI quintile levels showed higher rates for the three cancers. The burden of these six urologic diseases displayed diverse age and sex distribution patterns. In 2021, a high body mass index (BMI) contributed to 20.07% of kidney cancer deaths worldwide, while smoking accounted for 26.48% of bladder cancer deaths and 3.00% of prostate cancer deaths.
conclusionsThe global burden of 6 urologic diseases presents a significant public health challenge. Urgent international collaboration is essential to advance the improvement of urologic disease management, encompassing the development of effective diagnostic screening tools and the implementation of high-quality prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.